Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.69 |
| ▸ | PNP | P00491 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.44 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26079955 | 1.00 | MEN1 (0.71) | MEN1KMT2ATLR7PNPCYP3A4 | |
| SCHEMBL455853 | 1.00 | MEN1 (0.71) | MEN1KMT2ATLR7PNPCYP3A4 | |
| SCHEMBL10117778 | 1.00 | MEN1 (0.71) | MEN1KMT2ATLR7PNPCYP3A4 | |
| SCHEMBL6448926 | 0.90 | PNP (0.66) | MEN1KMT2ATLR7PNPCYP3A4 | |
| SCHEMBL28692399 | 0.88 | MEN1 (0.72) | MEN1KMT2ATLR7PNPCYP3A4 | |
| SCHEMBL6905072 | 0.87 | TLR7 (0.76) | MEN1KMT2ATLR7PNPCYP3A4 | |
| SCHEMBL7634608 | 0.87 | TLR7 (0.76) | MEN1KMT2ATLR7PNPCYP3A4 | |
| SCHEMBL26079973 | 0.87 | TLR7 (0.76) | MEN1KMT2ATLR7PNPCYP3A4 | |
| SCHEMBL23202214 | 0.87 | TLR7 (0.76) | MEN1KMT2ATLR7PNPCYP3A4 | |
| SCHEMBL23202549 | 0.87 | MEN1 (0.78) | MEN1KMT2ATLR7PNPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129077-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2025-04-24 | — | — | US | claimed |
| CN-112533607-B | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2025-01-07 | — | — | CN | claimed |
| EP-3801538-B1 | TLR7 AGONISTS | PRIMMUNE THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | claimed |
| EP-3801538-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| CN-112533607-A | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2021-03-19 | — | — | CN | claimed |
| US-20250129077-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2025-04-24 | — | — | US | disclosed |
| EP-4512816-A2 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-112533607-B | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-3801538-B1 | TLR7 AGONISTS | PRIMMUNE THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-12037335-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037335-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037335-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20220098198-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
| US-20220098198-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
| US-11059824-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059824-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3801538-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-112533607-A | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059824-B2 | Substituted purines as TLR7 agonists | TLR7, TLR9, TLR1 | MEN1 4315/4885KMT2A 2261/4885TLR7 1/4885 |
| US-12037335-B2 | Substituted purines as TLR7 agonists | TLR7, TLR9, TLR1 | MEN1 4315/4885KMT2A 2261/4885TLR7 1/4885 |
| US-20220098198-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | TLR7, TLR9, TLR1 | MEN1 4315/4885KMT2A 2261/4885TLR7 1/4885 |
| US-20250129077-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | TLR7, TLR9, TLR1 | MEN1 4315/4885KMT2A 2261/4885TLR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.